Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib

Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib

ABSTRACT Background In the phase 3 ponatinib‐3001 trial (PhALLCON, NCT03589326), ponatinib demonstrated superior efficacy over imatinib with comparable safety in patients with newly diagnosed Philadelphia‐positive acute lymphoblastic leukemia (Ph+ ALL). This post hoc analysis evaluated the net benef...

Full description

Saved in:
Bibliographic Details
Main Authors: Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, Pau Montesinos, Pankit Vachhani, Vanderson Rocha, Cristina Papayannidis, Jessica T. Leonard, Maria R. Baer, Jose‐Maria Ribera, James McCloskey, Jianxiang Wang, Deepali Rane, Shien Guo
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Cancer Medicine
Subjects:
acute lymphoblastic leukemia
imatinib
Philadelphia chromosome‐positive
ponatinib
Q‐TWiST analysis
quality of life
Online Access:https://doi.org/10.1002/cam4.70780
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70780

Similar Items